New Risk • Jun 30
New major risk - Revenue and earnings growth Earnings have declined by 7.6% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (27% average weekly change). Earnings have declined by 7.6% per year over the past 5 years. Revenue is less than US$1m. 공시 • Jun 25
Pegbio Co., Ltd. Announces Appointment of Yik Lam Liao as Non-Executive Director and Chairperson of the Audit Committee and A Member of Each of the Remuneration and Appraisal Committee and the Nomination Committee, Effective June 24, 2026 PegBio Co., Ltd. held its annual general meeting on June 24, 2026. Upon approval at the AGM, Ms. Yik Lam LIAO was appointed as an independent non-executive Director of the second session of the Board, for a term up to the expiration of the second session of the Board commencing from June 24, 2026. Ms. LIAO will serve as the chairperson of the Audit Committee and a member of each of the Remuneration and Appraisal Committee and the Nomination Committee, with a term of office consistent with her term as an independent non-executive Director of the second session of the Board. The biographical details of Ms. LIAO and the information required to be disclosed under Rule 13.51(2) of the Listing Rules are set out in the Circular. As at the date of this announcement, there have been no changes to such information. 공시 • Jun 02
PegBio Co., Ltd., Annual General Meeting, Jun 24, 2026 PegBio Co., Ltd., Annual General Meeting, Jun 24, 2026, at 10:00 China Standard Time. Location: 6/f, block a, no. 520 shaoxing road, gongshu district, zhejiang province, hangzhou China New Risk • May 05
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 2 years (CN¥66m net loss in 2 years). Share price has been volatile over the past 3 months (10% average weekly change). 공시 • Mar 11
PegBio Co., Ltd. to Report Fiscal Year 2025 Results on Mar 23, 2026 PegBio Co., Ltd. announced that they will report fiscal year 2025 results on Mar 23, 2026 Board Change • Feb 03
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. independent Non-Executive Director Xinpeng Fan was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • Dec 23
PegBio Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 299.99376 million. PegBio Co., Ltd. has completed a Follow-on Equity Offering in the amount of HKD 299.99376 million.
Security Name: H Shares
Security Type: Common Stock
Securities Offered: 5,136,000
Price\Range: HKD 58.41
Transaction Features: Subsequent Direct Listing 공시 • Aug 15
PegBio Co., Ltd. to Report First Half, 2025 Results on Aug 26, 2025 PegBio Co., Ltd. announced that they will report first half, 2025 results on Aug 26, 2025 New Risk • Aug 13
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Hong Kong stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-CN¥185m free cash flow). Earnings have declined by 11% per year over the past 5 years. Revenue is less than US$1m. Minor Risk Share price has been volatile over the past 3 months (11% average weekly change). Board Change • May 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 7 non-independent directors. independent Non-Executive Director Xinpeng Fan was the last independent director to join the board, commencing their role in 2024. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. 공시 • May 26
PegBio Co., Ltd. has completed an IPO in the amount of HKD 300.8226 million. PegBio Co., Ltd. has completed an IPO in the amount of HKD 300.8226 million.
Security Name: H Shares
Security Type: Common Stock
Securities Offered: 9,642,000
Price\Range: HKD 15.6
Discount Per Security: HKD 0.78
Security Name: H Shares
Security Type: Common Stock
Securities Offered: 57,000
Price\Range: HKD 15.6
Discount Per Security: HKD 0.78
Security Name: H Shares
Security Type: Common Stock
Securities Offered: 9,584,500
Price\Range: HKD 15.6
Discount Per Security: HKD 0.78
Transaction Features: Regulation S; Sponsor Backed Offering